Escitalopram Dosing and Management
Starting Dose
Start escitalopram at 10 mg once daily for most adults, taken either morning or evening with or without food 1. This is the FDA-approved starting dose for both major depressive disorder and generalized anxiety disorder.
Special Populations
Elderly patients (≥60 years): Start at 10 mg/day and maintain at this dose 1. The 10 mg dose is specifically recommended as the maximum for most elderly patients due to a 50% increase in half-life compared to younger adults 1.
Hepatic impairment: Start and maintain at 10 mg/day 1. Clearance is decreased and plasma concentrations are increased in hepatically impaired patients 1.
Adolescents (12-17 years): Start at 10 mg/day 1. Safety and effectiveness are established in this age group 1.
Children (<12 years): Not recommended—safety and effectiveness not established 1.
Dose Titration
If increasing the dose to 20 mg/day:
- Adults: Wait minimum 1 week before increasing 1
- Adolescents: Wait minimum 3 weeks before increasing 1
- Elderly/hepatic impairment: Generally maintain at 10 mg/day; do not routinely increase 1
The 20 mg dose showed efficacy in trials but did not demonstrate greater benefit than 10 mg in fixed-dose studies 1. Most patients (77%) in real-world settings require dose escalation beyond 10 mg to achieve therapeutic plasma concentrations 2.
Administration Timing
Take once daily, morning or evening—timing is flexible and food does not affect absorption 1. Peak plasma concentrations occur 3-4 hours post-dose 3.
Monitoring
Therapeutic Drug Monitoring (TDM)
- Therapeutic reference range: 15-80 ng/mL (escitalopram plasma concentration) 2
- Consider TDM at week 4 to guide dose adjustments, particularly in elderly patients or those with inadequate response 2
- Patients achieving therapeutic range by week 4 show significantly higher response and remission rates 2
Clinical Monitoring
- Baseline: Screen for personal/family history of bipolar disorder, mania, or hypomania before initiating 1
- Ongoing:
- Assess response every 1-2 weeks initially using standardized scales
- Monitor for hyponatremia, especially in elderly (headache, confusion, weakness, unsteadiness) 1
- Inquire specifically about sexual dysfunction at baseline and during treatment 1
- Monitor weight and growth in children/adolescents 1
- Check for bleeding risk if on NSAIDs, aspirin, or anticoagulants 1
CYP2C19 Considerations
CYP2C19 poor metabolizers have 2.1-fold higher exposure than extensive metabolizers 4. In elderly poor metabolizers, 10 mg/day may be the maximum appropriate dose, while extensive metabolizers may require up to 20 mg/day for therapeutic response 4, 5.
Side Effect Management
Common Adverse Effects (63% experience at least one) 6:
- Nausea/vomiting (most common reason for discontinuation): Take with food, start at lower dose if needed
- Fatigue/somnolence (41% in elderly): Consider evening dosing 7
- Sexual dysfunction: Discuss openly; may require dose reduction or medication change 1
- Diarrhea, dizziness, dry mouth, headache, sweating, tremor: Usually transient
Serious Adverse Effects
- Hyponatremia: More common in elderly; discontinue if symptomatic 1
- Bleeding: Caution with concurrent NSAIDs/anticoagulants 1
- Serotonin syndrome: Risk with MAOIs, linezolid, methylene blue—requires 14-day washout 1
- QTc prolongation: Average increase 5.5 ms, not concentration-dependent 2
Duration of Treatment
- First episode major depression: Minimum 4 months after response 6
- Recurrent depression: Consider prolonged/indefinite treatment 6
- Maintenance: Periodically reassess need for continued treatment 1
Maintenance efficacy is established in adults; one study showed benefit of continued treatment at 10-20 mg/day after acute response 1.
Tapering Schedule
Never stop abruptly—always taper gradually 1. Discontinuation symptoms are common with SSRIs.
Recommended Approach:
- Reduce dose gradually over several weeks rather than stopping abruptly
- If intolerable symptoms occur after dose reduction, resume previous dose and taper more slowly
- Monitor for discontinuation symptoms: dizziness, sensory disturbances, anxiety, confusion, headache 1
- No specific taper schedule provided in FDA labeling; clinical judgment required based on dose, duration, and patient factors
MAOI Transitions:
- Stopping escitalopram before starting MAOI: Wait 14 days 1
- Stopping MAOI before starting escitalopram: Wait 14 days 1
Key Clinical Pearls
- Steady-state concentrations achieved in 7-10 days 3
- Half-life 27-33 hours supports once-daily dosing 3
- Low protein binding (56%) minimizes drug interactions 3
- Escitalopram is preferred over paroxetine and fluoxetine in elderly due to lower adverse effect rates 6
- In elderly with comorbid depression and anxiety, escitalopram 10-20 mg/day shows significant improvement in both conditions 8
- Response rates in elderly: 69% vs 51% placebo (primary analysis), though intention-to-treat showed no significant difference 7